Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9309
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huang, Shiang-Fen | - |
dc.contributor.author | Wu, Alice Ying-Jung | - |
dc.contributor.author | Lee, Susan Shin-Jung | - |
dc.contributor.author | Huang, Yu-Shan | - |
dc.contributor.author | Lee, Chun-Yuan | - |
dc.contributor.author | Yang, Te-Liang | - |
dc.date.accessioned | 2024-12-19T03:41:40Z | - |
dc.date.available | 2024-12-19T03:41:40Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/9309 | - |
dc.description.abstract | Abstract COVID-19-associated mold infection (CAMI) is defined as development of mold infections in COVID-19 patients. Co-pathogenesis of viral and fungal infections include the disruption of tissue barrier following SARS CoV-2 infection with the damage in the alveolar space, respiratory epithelium and endothelium injury and overwhelming inflammation and immune dysregulation during severe COVID-19. Other predisposing risk factors permissive to fungal infections during COVID-19 include the administration of immune modulators such as corticosteroids and IL-6 antagonist. COVID-19-associated pulmonary aspergillosis (CAPA) and COVID-19-associated mucormycosis (CAM) is increasingly reported during the COVID-19 pandemic. CAPA usually developed within the first month of COVID infection, and CAM frequently arose 10e15 days post diagnosis of COVID-19. Diagnosis is challenging and often indistinguishable during the cytokine storm in COVID-19, and several diagnostic criteria have been proposed. Development of CAPA and CAM is associated with a high mortality despiteappropriate anti-mold therapy. Both isavuconazole and amphotericin B can be used for treatment of CAPA and CAM; voriconazole is the primary agent for CAPA and posaconazole is an alternative for CAM. Aggressive surgery is recommended for CAM to improve patient survival. A high index of suspicion and timely and appropriate treatment is crucial to improve patient outcome. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier Taiwan LLC | en_US |
dc.subject | Aspergillosis | en_US |
dc.subject | Mucormycosis | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | CAPA | en_US |
dc.subject | CAM | en_US |
dc.title | COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 56 NO 3 2023 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
442-454.pdf | 1.97 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.